Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors

被引:52
作者
Boivin, G
Goyette, N
机构
[1] CHU Laval, CHUQ, Res Ctr Infect Dis, Quebec City, PQ G1V 4G2, Canada
[2] Univ Laval, Dept Med Biol, Quebec City, PQ, Canada
关键词
influenza B; inhibitors; virus; influenza A;
D O I
10.1016/S0166-3542(01)00219-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Forty-two influenza A and 23 influenza B isolates collected from untreated subjects during the 1999-2000 influenza season in Canada were tested for their susceptibility to three neuraminidase inhibitors (zanamivir, oseltamivir carboxylate and RWJ-270201 or BCX-1812) using a chemiluminescent neuraminidase assay. Influenza B isolates were less susceptible than A viruses to all tested drugs. RWJ-270201 was the most potent drug against both influenza A(H3N2) (mean IC50: 0.60 nM) and B (mean IC50: 0.87 nM) viruses. Oseltamivir carboxylate was more active than zanamivir for influenza A(H3N2) isolates (mean IC50: 0.73 vs. 2.09 nM) whereas it was less potent against B viruses (mean IC50): 11.53 vs. 4.15 nM). (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:143 / 147
页数:5
相关论文
共 15 条
  • [1] Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir
    Bantia, S
    Parker, CD
    Ananth, SL
    Horn, LL
    Andries, K
    Chand, P
    Kotian, PL
    Dehghani, A
    El-Kattan, Y
    Lin, T
    Hutchison, TL
    Montgomery, JA
    Kellog, DL
    Babu, YS
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) : 1162 - 1167
  • [2] Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies
    Barnett, JM
    Cadman, A
    Gor, D
    Dempsey, M
    Walters, M
    Candlin, A
    Tisdale, M
    Morley, PJ
    Owens, IJ
    Fenton, RJ
    Lewis, AP
    Claas, ECJ
    Rimmelzwaan, GF
    De Groot, R
    Osterhaus, ADME
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) : 78 - 87
  • [3] Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults
    Boivin, G
    Goyette, N
    Hardy, I
    Aoki, F
    Wagner, A
    Trottier, S
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (04) : 1471 - 1474
  • [4] Evaluation of a rapid optical immunoassay for influenza viruses (FLU OIA test) in comparison with cell culture and reverse transcription-PCR
    Boivin, G
    Hardy, I
    Kress, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (02) : 730 - 732
  • [5] Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir
    Buxton, RC
    Edwards, B
    Juo, RR
    Voyta, JC
    Tisdale, M
    Bethell, RC
    [J]. ANALYTICAL BIOCHEMISTRY, 2000, 280 (02) : 291 - 300
  • [6] Drug therapy: Prevention and treatment of influenza.
    Couch, RB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (24) : 1778 - 1787
  • [7] Influenza virus neuraminidase inhibitors
    Gubareva, LV
    Kaiser, L
    Hayden, FG
    [J]. LANCET, 2000, 355 (9206) : 827 - 835
  • [8] GUBAREVA LV, 1999, 2 INT S INFL OTH RES
  • [9] Inhaled zanamivir for the prevention of influenza in families.
    Hayden, FG
    Gubareva, LV
    Monto, AS
    Klein, TC
    Elliott, MJ
    Hammond, JM
    Sharp, SJ
    Ossi, MJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (18) : 1282 - 1289
  • [10] Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections
    Hayden, FG
    Osterhaus, ADME
    Treanor, JJ
    Fleming, DM
    Aoki, FY
    Nicholson, KG
    Bohnen, AM
    Hirst, HM
    Keene, O
    Wightman, K
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (13) : 874 - 880